Business Description
Xbrane Biopharma AB
ISIN : SE0007789409
Compare
Compare
Traded in other countries / regions
XBRANE.Sweden7XB.GermanyXBRANs.UK IPO Date
2016-02-03Description
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. Xbrane's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.18 | |||||
| Equity-to-Asset | 0.31 | |||||
| Debt-to-Equity | 0.66 | |||||
| Debt-to-EBITDA | -0.67 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -2.83 | |||||
| Beneish M-Score | -2.82 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 177.8 | |||||
| 3-Year EBITDA Growth Rate | 3.2 | |||||
| 3-Year EPS without NRI Growth Rate | 3.5 | |||||
| 3-Year FCF Growth Rate | -3.3 | |||||
| 3-Year Book Growth Rate | -20.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 51.17 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 49.97 | |||||
| 9-Day RSI | 42.09 | |||||
| 14-Day RSI | 41.24 | |||||
| 6-1 Month Momentum % | -34.17 | |||||
| 12-1 Month Momentum % | -84.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.35 | |||||
| Quick Ratio | 0.9 | |||||
| Cash Ratio | 0.06 | |||||
| Days Inventory | 819.3 | |||||
| Days Sales Outstanding | 58.91 | |||||
| Days Payable | 387.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.3 | |||||
| Shareholder Yield % | -158.97 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 61.87 | |||||
| Operating Margin % | -130.4 | |||||
| Net Margin % | -185.45 | |||||
| FCF Margin % | -172.11 | |||||
| ROE % | -126.78 | |||||
| ROA % | -44.97 | |||||
| ROIC % | -41.93 | |||||
| ROC (Joel Greenblatt) % | -308.3 | |||||
| ROCE % | -59.15 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 8.23 | |||||
| PS Ratio | 0.43 | |||||
| PB Ratio | 0.96 | |||||
| Price-to-Tangible-Book | 1.83 | |||||
| EV-to-EBIT | -1.54 | |||||
| EV-to-Forward-EBIT | 4.13 | |||||
| EV-to-EBITDA | -1.54 | |||||
| EV-to-Forward-EBITDA | 4.13 | |||||
| EV-to-Revenue | 1.96 | |||||
| EV-to-Forward-Revenue | 0.78 | |||||
| EV-to-FCF | -1.13 | |||||
| Price-to-Net-Current-Asset-Value | 4.12 | |||||
| Earnings Yield (Greenblatt) % | -64.88 | |||||
| FCF Yield % | -136.36 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xbrane Biopharma AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 199.811 | ||
| EPS (TTM) (kr) | -0.99 | ||
| Beta | 0 | ||
| Volatility % | 360.55 | ||
| 14-Day RSI | 41.24 | ||
| 14-Day ATR (kr) | 0.010821 | ||
| 20-Day SMA (kr) | 0.1692 | ||
| 12-1 Month Momentum % | -84.03 | ||
| 52-Week Range (kr) | 0.1262 - 1.994 | ||
| Shares Outstanding (Mil) | 1,532.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Xbrane Biopharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Xbrane Biopharma AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Xbrane Biopharma AB Frequently Asked Questions
What is Xbrane Biopharma AB(OSTO:XBRANE)'s stock price today?
The current price of OSTO:XBRANE is kr0.16. The 52 week high of OSTO:XBRANE is kr1.99 and 52 week low is kr0.13.
When is next earnings date of Xbrane Biopharma AB(OSTO:XBRANE)?
The next earnings date of Xbrane Biopharma AB(OSTO:XBRANE) is 2025-02-21.
Does Xbrane Biopharma AB(OSTO:XBRANE) pay dividends? If so, how much?
Xbrane Biopharma AB(OSTO:XBRANE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers